🇺🇸 ABT-267 in United States

77 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 22 April 2025 – 22 April 2026
• Total reports: 77

Most-reported reactions

1. Anaemia — 14 reports (18.18%)
2. Hyperbilirubinaemia — 14 reports (18.18%)
3. Jaundice — 10 reports (12.99%)
4. Diarrhoea — 7 reports (9.09%)
5. Dehydration — 6 reports (7.79%)
6. Dyspnoea — 6 reports (7.79%)
7. Blood Bilirubin Increased — 5 reports (6.49%)
8. Chest Pain — 5 reports (6.49%)
9. Confusional State — 5 reports (6.49%)
10. Encephalopathy — 5 reports (6.49%)

Source database →

Frequently asked questions

Is ABT-267 approved in United States?

ABT-267 does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for ABT-267 in United States?

AbbVie (prior sponsor, Abbott) is the originator. The local marketing authorisation holder may differ — check the official source linked above.